View in EDS HTML Full Text PDF Full Text

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Saved in:
Bibliographic Details
Title: A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.
Authors: Sborov, Douglas W.1 (AUTHOR), Canella, Alessandro2 (AUTHOR), Hade, Erinn M.3 (AUTHOR), Mo, Xiaokui3 (AUTHOR), Khountham, Soun2 (AUTHOR), Wang, Jiang2 (AUTHOR), Ni, Wenjun4 (AUTHOR), Poi, Ming2,4 (AUTHOR), Coss, Christopher2,4 (AUTHOR), Liu, Zhongfa4 (AUTHOR), Phelps, Mitch A.2,4 (AUTHOR), Mortazavi, Amir5 (AUTHOR), Andritsos, Leslie6 (AUTHOR), Baiocchi, Robert A.6 (AUTHOR), Christian, Beth A.6 (AUTHOR), Benson, Don M.6 (AUTHOR), Flynn, Joseph6 (AUTHOR), Porcu, Pierluigi6 (AUTHOR), Byrd, John C.6 (AUTHOR), Pichiorri, Flavia7 (AUTHOR)
Source: Leukemia & Lymphoma. Oct2017, Vol. 58 Issue 10, p2310-2318. 9p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:10428194
DOI:10.1080/10428194.2017.1298751